The role of cancer cell bioenergetics in dormancy and drug resistance. Cancer Metastasis Rev 2023 Mar;42(1):87-98
Date
01/26/2023Pubmed ID
36696004Pubmed Central ID
PMC10233409DOI
10.1007/s10555-023-10081-7Scopus ID
2-s2.0-85146873515 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
While anti-cancer drug treatments are often effective for the clinical management of cancer, these treatments frequently leave behind drug-tolerant persister cancer cells that can ultimately give rise to recurrent disease. Such persistent cancer cells can lie dormant for extended periods of time, going undetected by conventional clinical means. Understanding the mechanisms that such dormant cancer cells use to survive, and the mechanisms that drive emergence from dormancy, is critical to the development of improved therapeutic strategies to prevent and manage disease recurrence. Cancer cells often exhibit metabolic alterations compared to their non-transformed counterparts. An emerging body of evidence supports the notion that dormant cancer cells also have unique metabolic adaptations that may offer therapeutically targetable vulnerabilities. Herein, we review mechanisms through which cancer cells metabolically adapt to persist during drug treatments and develop drug resistance. We also highlight emerging therapeutic strategies to target dormant cancer cells via their metabolic features.
Author List
Tau S, Miller TWAuthor
Todd W. Miller PhD Professor in the Pharmacology and Toxicology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsDrug Resistance, Neoplasm
Energy Metabolism
Humans
Neoplasms
